With molecular profiling, researchers may be able to identify potential actionable targets that could lead to additional treatment strategies in pancreatic cancer, explains Ferraro. A number of preclinical and phase I studies are being done, and further research could lead to larger phase II/III studies. Watch here. . .
Pablo Ferraro, MD, medical oncologist, Memorial Healthcare System, discusses the use of molecular profiling in pancreatic cancer.